CD274 and head and neck squamous cell carcinoma: When used in combination with anti-PD-L1 antibody durvalumab or anti-CTLA-4 antibody tremelimumab, mogamulizumab failed to show significant efficacy in a phase I trial that included patients with advanced solid tumors, including HNSCC [130].